What is Roth Capital’s Forecast for CervoMed Q1 Earnings?

CervoMed Inc. (NASDAQ:CRVO) – Roth Capital issued their Q1 2026 EPS estimates for CervoMed in a research note issued on Tuesday, March 18th. Roth Capital analyst B. Pachaiyappan forecasts that the company will post earnings per share of ($0.52) for the quarter. Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Roth Capital also issued estimates for CervoMed’s Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.90) EPS and FY2026 earnings at ($2.76) EPS.

A number of other research firms have also weighed in on CRVO. Morgan Stanley reissued an “underweight” rating on shares of CervoMed in a report on Wednesday, December 11th. Brookline Capital Management raised shares of CervoMed from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 11th. HC Wainwright downgraded CervoMed from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 17th. D. Boral Capital restated a “buy” rating and issued a $10.00 price target on shares of CervoMed in a research report on Monday. Finally, Canaccord Genuity Group raised their price target on CervoMed from $12.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $27.50.

CervoMed Stock Performance

CRVO stock opened at $11.56 on Wednesday. The firm has a fifty day moving average price of $3.06 and a 200 day moving average price of $7.90. CervoMed has a fifty-two week low of $1.80 and a fifty-two week high of $25.92. The firm has a market cap of $71.33 million, a PE ratio of -5.69 and a beta of 1.84.

CervoMed (NASDAQ:CRVO) last posted its earnings results on Monday, March 17th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%. The business had revenue of $2.16 million during the quarter, compared to analysts’ expectations of $1.51 million.

Institutional Trading of CervoMed

A number of institutional investors have recently bought and sold shares of CRVO. Virtu Financial LLC bought a new stake in shares of CervoMed during the fourth quarter worth $26,000. DRW Securities LLC bought a new stake in shares of CervoMed during the fourth quarter worth $30,000. Mariner LLC bought a new stake in shares of CervoMed during the fourth quarter worth $30,000. BNP Paribas Financial Markets bought a new stake in shares of CervoMed during the fourth quarter worth $32,000. Finally, JPMorgan Chase & Co. lifted its position in shares of CervoMed by 251.8% during the fourth quarter. JPMorgan Chase & Co. now owns 14,464 shares of the company’s stock worth $34,000 after purchasing an additional 10,352 shares during the last quarter. 25.15% of the stock is currently owned by institutional investors.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.